Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment
Status:
Completed
Trial end date:
2021-01-18
Target enrollment:
Participant gender:
Summary
The proposed study is a prospective, open-label, unicentric, phase IV clinical trial.
This study is design to find new efficacy biomarkers for IKERVIS® (1mg/mL ciclosporin) eye
drops after 1 and 3 month after initiation of therapy. Additionally, this study intends to
investigate whether IKERVIS® will help patients to better overcome situations of desiccating
stress by exposing them to an adverse controlled environment (ACE) and analyzing both
clinical and molecular parameters.
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA